MDM2 and acute myeloid leukemia: Indeed, ongoing clinical studies with MDM2 antagonists such as idasanutlin (NCT02545283), milademetan (NCT03634228), and KRT-232 (NCT03041688) are being actively conducted in R/R AML patients.